Metastatic colorectal cancer

2002, Que faire devant un cancer digestif en 2003? Recommandations de la Fédération Francophone de Cancérologie Digestive (FFCD) 1ère partie, Gastroenterol Clin Biol, 26, 1140 Adenis, 1998, Standards, options et recommandations pour la prise en charge des patients atteints de cancer du colon Conroy, 2004, Recommandations pour la pratique clinique : Mise à jour 2003 des Standards, Options et Recommandations pour la prise en charge par chimiothérapie palliative de première ligne des patients atteints d’un cancer colorectal métastatique (mise à jour 2003), Gastroenterol Clin Biol, 28, E1 GERCOR. Les Recommandations thérapeutiques (côlon) [on line]. 2005 Conférence de Consensus. Conclusions et recommandations du jury. Texte de Consensus. Prévention, dépistage et prise en charge des cancers du côlon. Gastroenterol Clin Biol 1998 22:S275-88. Recommandations pour la pratique clinique : prise en charge thérapeutique des métasatases hépatiques des cancers colorectaux. Gastroenterol Clin Biol 2003 27:B1-B104. Fervers, 1995, Méthodologie de développement des Standards, Bull Cancer, 82, 761 Fervers, 2001, SOR: project methodology, Br J Cancer, 84, 8, 10.1054/bjoc.2000.1757 Gallix, 2003, Quels sont les examens à réaliser dans le bilan d’extension préthérapeutique? Critères de qualité et résultats attendus, Gastroenterol Clin Biol, 27, B25 Chiche, 2003, Quelles métastases hépatiques sont résécables d’emblée?, Gastroenterol Clin Biol, 27, B41 Nordlinger, 1996, Surgical resection of colorectal carcinoma metastases to the liver, Cancer, 77, 1254, 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.0.CO;2-I Fong, 1997, Liver resection for colorectal metastases, J Clin Oncol, 15, 938, 10.1200/JCO.1997.15.3.938 Rivoire, 2003, Peut-on rendre résécables des métastases hépatiques initialement non résécables?, Gastroenterol Clin Biol, 27, B88 Elias, 1995, Is simultaneous hepatectomy and intestinal anatomosis safe?, Am J Surg, 169, 254, 10.1016/S0002-9610(99)80146-9 Elias, 2002, Preoperative selective portal vein embolization before hepatectomy for liver metastaese : long term results and impact on survival, Surgery, 131, 294, 10.1067/msy.2002.120234 Adam, 2000, Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors, Ann Surg, 232, 777, 10.1097/00000658-200012000-00006 Elias, 2004, Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases, Hepatogastroenterology, 51, 1788 Guimbaud, 2003, Quelle est la place de la chimiothérapie néoadjuvante, adjuvante et palliative dans la prise en charge des métastases hépatiques d’origine colorectale?, Gastroenterol Clin Biol, 27, B63 Parikh, 2002, Radiofrequency ablation of hepatic metastases, Semin Oncol, 29, 168, 10.1053/sonc.2002.31673 De Baere, 2003, Modalités et faisabilité des traitements par destruction locale des métastases hépatiques, Gastroenterol Clin Biol, 27, B80 Glehen, 2004, Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study, J Clin Oncol, 22, 3284, 10.1200/JCO.2004.10.012 Glehen, 2004, Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin, Br J Surg, 91, 747, 10.1002/bjs.4473 Verwaal, 2003, Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer, J Clin Oncol, 21, 3737, 10.1200/JCO.2003.04.187 Köhne, 2002, Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients, Ann Oncol, 20, 308, 10.1093/annonc/mdf034 de Gramont, 1997, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study, J Clin Oncol, 15, 808, 10.1200/JCO.1997.15.2.808 Douillard, 2000, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet, 355, 1041, 10.1016/S0140-6736(00)02034-1 Tournigand, 2004, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study, J Clin Oncol, 22, 229, 10.1200/JCO.2004.05.113 Mitry, 2004, Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer – A pooled analysis of 254 patients included in 2 randomised trials (abstract), Proc Am Soc Clin Oncol, 23, 3576a, 10.1200/jco.2004.22.14_suppl.3576 de Gramont, 2000, Leucovorin and 5-fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol, 18, 2938, 10.1200/JCO.2000.18.16.2938 Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046 Kabbinavar, 2005, Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial, J Clin Oncol, 23, 3697, 10.1200/JCO.2005.05.112 Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, 60, 10.1200/JCO.2003.10.066 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 De Gramont, 2004, OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer (abstract), Proc Am Soc Clin Oncol, 23, 251a Maughan, 2003, Lancet, 361, 457, 10.1016/S0140-6736(03)12461-0 Tournigand, 1998, A simplified bimonthly regiment with leucovorin (LV) and 5-fluorouracil (5FU) for metastatic colorectal cancer (MCRC) (abstract), Proc Am Soc Clin Oncol, 17, 274a Bouché, 2003, Essai randomisé comparant trois schémas différents de 5FU continu et le raltirexed en première ligne pour métastases de cancer colo-rectal: résultats de l’essai de phase III multicentrique FFCD 9601 (abstract), Gastroenterol Clin Biol, 27, A70 van Cutsem, 2001, Oral Capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study, J Clin Oncol, 19, 4097, 10.1200/JCO.2001.19.21.4097 Hoff, 2001, Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer : results of a randomized phase III study, J Clin Oncol, 19, 2282, 10.1200/JCO.2001.19.8.2282 Douillard, 2002, Multicenter phase III study of uracil/ tegafur UFT and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 20, 3605, 10.1200/JCO.2002.04.123 Carmichael, 2002, Randomized comparative study of tegafur/uracil plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer, J Clin Oncol, 20, 3617, 10.1200/JCO.2002.10.129 Cassidy, 2004, XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer, J Clin Oncol, 22, 2084, 10.1200/JCO.2004.11.069 Bajetta, 2004, Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma, Cancer, 100, 279, 10.1002/cncr.11910 Borner, 2005, A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity, Ann Oncol, 16, 282, 10.1093/annonc/mdi047 1996, Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer, J Natl Cancer Inst, 88, 252, 10.1093/jnci/88.5.252 Rougier, 1992, Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma : long-term results of a prospective randomized trial, J Clin Oncol, 10, 1112, 10.1200/JCO.1992.10.7.1112 Kerr, 2003, Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases : a multicentre randomised trial, Lancet, 361, 368, 10.1016/S0140-6736(03)12388-4 Gamelin, 1996, Relationship between 5-fluorouracil (5FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5FU, Cancer, 77, 441, 10.1002/(SICI)1097-0142(19960201)77:3<441::AID-CNCR4>3.0.CO;2-N Gamelin, 1998, Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients, J Clin Oncol, 16, 1470, 10.1200/JCO.1998.16.4.1470 Cunningham, 1996, Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Tomudex colorectal cancer study group, Ann Oncol, 7, 961, 10.1093/oxfordjournals.annonc.a010800 Cocconi, 1998, Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex colorectal cancer study group, J Clin Oncol, 16, 2943, 10.1200/JCO.1998.16.9.2943 Maughan, 2002, Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial, Lancet, 359, 1555, 10.1016/S0140-6736(02)08514-8 Seitz, 2002, Multicenter non-randomized phase II study of raltitrexed and oxaliplatin in non pre-treated metastatic colorectal cancer patients, Ann Oncol, 13, 1072, 10.1093/annonc/mdf183 Scheithauer, 2001, Second line treatment with oxaliplatin plus raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy, Ann Oncol, 12, 709, 10.1023/A:1011194712661 Scheithauer, 2002, Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer, J Clin Oncol, 20, 165, 10.1200/JCO.20.1.165 Saltz, 2000, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer, N Engl J Med, 343, 905, 10.1056/NEJM200009283431302 Becouarn, 1998, Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers, J Clin Oncol, 16, 2739, 10.1200/JCO.1998.16.8.2739 Ducreux, 1999, Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer, J Clin Oncol, 17, 2901, 10.1200/JCO.1999.17.9.2901 André, 1999, CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer, Eur J Cancer, 35, 1343, 10.1016/S0959-8049(99)00150-1 André, 1999, Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen, J Clin Oncol, 17, 3560, 10.1200/JCO.1999.17.11.3560 Maindrault-Goebel, 1999, Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR, Eur J Cancer, 35, 1338, 10.1016/S0959-8049(99)00149-5 Maindrault-Goebel, 2000, Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour-5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer, Ann Oncol, 11, 1477, 10.1023/A:1026520812351 Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, 337, 10.1056/NEJMoa033025 Giantonio, 2005, High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (abstract), Proc Am Soc Clin Oncol, 23, 2a, 10.1200/jco.2005.23.16_suppl.2 Chung, 2005, Cetuximab shows activity in colorectal cancer patients with tumors that do not express the Epidermal Growth Factor Receptor by immunohistochemistry, J Clin Oncol, 23, 1803, 10.1200/JCO.2005.08.037 Scartozzi, 2004, Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies, J Clin Oncol, 22, 4720, 10.1200/JCO.2004.00.117 Maindrault-Goebel, 2004, Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer, Ann Oncol, 15, 1210, 10.1093/annonc/mdh305 Ross, 1997, A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer, Ann Oncol, 8, 995, 10.1023/A:1008263516099 Chester, 2000, Protracted infusional 5-fluorouracil (5FU) with bolus mitomycin C in 5-FU-resistant colorectal cancer, Ann Oncol, 11, 235, 10.1023/A:1008356017611 Seitz, 1998, 5Fluorouracil, high dose folinic acid and mitomycin-C combination chemotherapy in previously treated patients with advanced colorectal carcinomas, J Chemotherapy, 10, 258, 10.1179/joc.1998.10.3.258 Mitry, 2002, Chemotherapy with capecitabine and mitomycin in patients with advanced colorectal cancer: preliminary results (abstract), Ann Oncol, 13, 86a Harba, 2003, Capecitabine/mitomycin C as salvage therapy in oxaliplatin and CPT11 refractory advanced colorectal carcinoma (abstract), Proc Am Soc Clin Oncol, 22, 332a Rougier, 1995, Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Francaise de Cancerologie Digestive, Br J Surg, 82, 1397, 10.1002/bjs.1800821034 Louafi, 2005, Cancer colorectal métastasé: faut-il retirer le primitif? (abstract), Gastroenterol Clin Biol, 29, A6 Scoggins, 1999, Nonoperative management of primary colorectal cancer in patients with stage IV disease, Ann Surg Oncol, 6, 651, 10.1007/s10434-999-0651-x Tebbutt, 2003, Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases, Gut, 52, 568, 10.1136/gut.52.4.568 Pautrat, 2003, Faut il réséquer la tumeur primitive en cas de cancer colorectal avec métastases hépatiques (MH) synchrones non résécables? Etude cas-témoins chez 59 malades, Ann Chir, 128, 657 Michel, 2004, Colorectal cancer with non-resectable synchronous metastases : should the primary tumor be resected ?, Gastroenterol Clin Biol, 28, 434, 10.1016/S0399-8320(04)94952-4 Conroy, 1998, Standards, options et recommandations pour la surveillance après traitement d’un cancer du côlon, Bull Cancer, 85, 152